|
Group Contends FDA Tobacco
Subcommittee Violates Advisory Panel Law
Days before an FDA advisory panel on tobacco meets, a government watchdog is
targeting a sub-group of the board, saying it has not been improperly established
and is inherently substantially influenced by FDA, with a source close to the issue
encouraging FDA and the White House’s Office of Management and Budget to
act or the agency could face litigation.
Click here to read more
A Summary of the Statement by Jim Tozzi, Center for Regulatory Effectiveness
before TPSAC August 30, 2010
Click here to read more
FDA Domination of the TPSAC Proceeding
From the onset CRE has expressed its concerns regarding FDA domination of the proceedings. FDA’s actions at the TPSAC meeting on August 30 provide ample justification for CRE’s concerns.
Click here to read more
|
